BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference

BioStem Technologies will share a prerecorded fireside chat and engage investors at the H.C. Wainwright 28th Annual Global Investment Conference.

Rhea-AI Summary

BioStem Technologies (BSEM)/b) announced that its management will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY, with conference participation scheduled for Monday, September 14.A prerecorded fireside chat will be available starting Friday, September 11, 2026, at 7:00 AM ET, and interested investors can access live and archived webcasts through the investors section of BioStem’s website at ir.biostemtechnologies.com. BioStem develops, manufactures, and commercializes perinatal tissue allograft products using its proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, and its portfolio includes Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.

Market Context

BioStem’s August 14 conference announcement preceded a -6.54% 24-hour reaction, showing that present...

Analysis

BioStem’s August 14 conference announcement preceded a -6.54% 24-hour reaction, showing that presentation notices had not consistently translated into positive trading outcomes. The September webcast remained the next concrete information point, with low short positioning as context.

Key Figures

Conference edition: 28th annual Conference attendance date: Monday, September 14 Webcast access date: Friday, September 11, 2026 +1 more

4 metrics

Conference edition 28th annual H.C. Wainwright Global Investment Conference

Conference attendance date Monday, September 14 H.C. Wainwright Global Investment Conference

Webcast access date Friday, September 11, 2026 Fireside chat

Webcast time 7:00 AM ET Fireside chat access

Historical Context

5 past events · Latest: Aug 14 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 14	Conference presentation	Neutral	-6.5%	Management presentation announcement preceded a negative 24-hour share-price reaction.
Aug 12	Q2 earnings report	Negative	-18.4%	Quarterly results included a net loss, EBITDA loss, and lower year-over-year revenue.
Aug 06	Nasdaq uplisting	Positive	+1.8%	Nasdaq approved common-stock listing on the Nasdaq Capital Market.
Jul 29	Earnings call scheduling	Neutral	-2.4%	Company scheduled its second-quarter results release and conference call.
Jul 10	Form 10 filing	Positive	+14.7%	Company filed a Form 10 registration statement and reaffirmed its Nasdaq plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

BioStem’s selected recent news reactions were mixed, with three events aligned to the announcement sentiment and two diverging.

Key Terms

perinatal tissue allograft, allograft, cgmp

3 terms

perinatal tissue allograft medical

"focused on the development, manufacturing, and commercialization of perinatal tissue allograft products"

Perinatal tissue allograft is biological material taken from tissues associated with childbirth—such as placenta, umbilical cord, amniotic membrane or fluid—and processed from one human donor to be implanted or applied to a different patient. Think of it as donated birth-related tissue used like a spare part to support healing or tissue repair in another person. It matters to investors because these grafts are regulated medical products used in wound care, orthopedics and regenerative medicine, so their safety, supply chain, and regulatory status affect commercial prospects.

allograft medical

"BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing"

Tissue taken from one person and transplanted into another to repair or replace damaged body parts, such as bone, skin, or heart valves. For investors, allografts matter because their use involves manufacturing standards, supply and safety controls, regulatory approvals, and reimbursement rules that can affect sales, liability and growth for companies that process, store or sell these biological materials — similar to how sourcing and quality control of key parts affect a manufacturer’s business.

cgmp regulatory

"and current Good Manufacturing Practices (“cGMP”)."

cGMP (current Good Manufacturing Practice) are government-enforced quality standards that manufacturers must follow to ensure drugs, medical devices, and related products are made consistently, safely, and meet specified quality tests. For investors, cGMP compliance is like a restaurant passing health inspections: it reduces the risk of product recalls, regulatory fines, or production stoppages that can hurt revenue and company value, and it supports market access and long-term trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

POMPANO BEACH, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY and is scheduled to attend the conference on Monday, September 14.

The Company’s fireside chat will be available for access on Friday, September 11, 2026, at 7:00 AM ET. Interested parties may access live and archived webcasts of the fireside chat on the “investors” section of the Company’s website at: ir.biostemtechnologies.com.

About BioStem Technologies, Inc. (Nasdaq: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the Association for Advancing Tissue and Biologics (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.

Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.

Contact BioStem:
Website: www.biostemtechnologies.com
E-Mail: pr@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342

Investor Relations:
Philip Trip Taylor, Gilmartin
ir@biostemtech.com

Public Relations:
Jennifer Horton, Relevance
jennifer@relevance.com

FAQ

When will BioStem Technologies (BSEM) present at the H.C. Wainwright 28th Annual Global Investment Conference?

BioStem Technologies management is scheduled to attend and present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on Monday, September 14, as disclosed in the announcement.

When will the BioStem Technologies (BSEM) fireside chat webcast be available?

The BioStem Technologies fireside chat for the H.C. Wainwright 28th Annual Global Investment Conference will be available starting Friday, September 11, 2026, at 7:00 AM ET, with both live and archived access offered.

How can investors access the BioStem Technologies (BSEM) webcast for the H.C. Wainwright conference?

Interested parties may access live and archived webcasts of BioStem Technologies’ fireside chat via the “investors” section of its website at ir.biostemtechnologies.com, as stated by the company.

What type of company is BioStem Technologies (BSEM) that is presenting at the H.C. Wainwright conference?

BioStem Technologies is a publicly traded biomedical company focused on developing, manufacturing and commercializing advanced allograft solutions from perinatal tissue, using its BioRetain®, CryoTek® and SteriTek® technologies across brands such as Neox®, Clarix®, VENDAJE® and American Amnion™.

Which BioStem Technologies (BSEM) products are highlighted in connection with its H.C. Wainwright conference appearance?

BioStem Technologies highlights allograft product lines including Neox®, Clarix®, VENDAJE® and American Amnion™, which are derived from perinatal tissue and used by clinicians across a range of medical specialties.